FDA is consolidating its responsibi...

FDA is consolidating its responsibility for reviewing novel pharmaceutical products into its Center for remedy Evaluation and Research (CDER) This work is commonly done, in part, by the Center for Biologics Evaluation and Research (CBER) and CDER
This action will allow CBER to focus its expertise forward vaccines, blood safety, gene therapy, and tissue